New Concepts in ADT- Thomas Keane
April 8, 2018
Tom Keane brings new concepts in androgen deprivation therapy (ADT) to light specifically discussing agonists versus antagonists, new androgen receptor-targeted drugs, including immunotherapy biomarkers, and genomic testing. He reviews the current state of the CRPC treatment and ADT options for use in advanced metastatic disease and concludes with a discussion on treating earlier versus later disease.
Thomas E. Keane, MBBCh, FRCSI, FACS
A Phase II Study of Docetaxel Before Medical Castration With Degarelix in Patients With Newly Diagnosed Metastatic Prostatic Adenocarcinoma.
Watch: Navigating the Adverse Effects of ADT - Neal Shore
Watch: Bones, Hot Flashes and ADT: Using with Chemotherapy and Timing - Thomas Keane
Watch: ADT Impact on Cardiovascular Health - Jehonathan Pinthus